EC approves Regeneron’s immunotherapy for cervical cancer
Pharmaceutical Technology
NOVEMBER 23, 2022
Based on the open-label, multicentre, international Phase III EMPOWER-Cervical 1 clinical trial findings, the regulatory agency granted approval in advanced cervical cancer. Additionally, 21% of subjects who received Libtayo had immune-mediated adverse reactions.
Let's personalize your content